Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs- Report 2014 pp 717–726Cite as

Hypophysen- und Hypothalamushormone

  • Chapter

  • 1530 Accesses

Zusammenfassung

Hauptvertreter der Hypophysen- und Hypothalamushormone sind Wachstumshormon, Somatostatin, Gonadotropinpräparate und Vasopressinanaloga. Wachstumshormonpräparate haben ihre bisherige Aufwärtsentwicklung nicht weiter fortgesetzt, sind aber mit Kosten von 190 Mio. € weiterhin die umsatzstärkste Gruppe der Hypophysen-und Hypothalamushormone. Leichte Zunahmen zeigen Somatostatinanaloga (86 Mio. €) und Follitropinpräparate (48 Mio. €). Die Verordnungskosten der Vasopressinanaloga für die Behandlung des zentralen Diabetes insipidus waren annähernd konstant (17 Mio. €).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Al-Inany HG, Abou-Setta AM, Aboulghar M (2006): Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006 Jul 19; 3: CD00175–0

    Google Scholar 

  • Andrejak M, Tribouilloy C (2013): Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 106: 333–339

    Article  PubMed  Google Scholar 

  • de Mouzon J, Allavena E, Schmitt C, Frappe M (2004): In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost. Gynecol Obstet Fertil 32: 508–518. [Article in French]

    Article  CAS  PubMed  Google Scholar 

  • Fleseriu M (2011): Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14: 184–193

    Article  PubMed  Google Scholar 

  • International Recombinant Human Chorionic Gonadotropin Study Group (2001): Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75: 1111–1118

    Google Scholar 

  • Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007): Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146: 104–115

    Article  PubMed  Google Scholar 

  • Löndahl M, Nilsson A, Lindgren H, Katzman P (2008): A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia. Eur J Endocrinol 158: 583–585

    Article  PubMed  Google Scholar 

  • Melmed S (2006): Acromegaly. N Engl J Med 355: 2558–2573

    Article  PubMed  Google Scholar 

  • National Institute for Clinical Excellence (NICE) (2002): Guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal No. 42. Internet: www.nice.org.uk/page.aspx?o= TA042guidance

    Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2003): Human growth hormone (somatropin) in adults with growth hormone deficiency. Technology Appraisal 64. Internet: www.nice.org.uk/page.aspx?o=TA064guidance

    Google Scholar 

  • Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A (2010): Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 94: 2467–2469

    Article  PubMed  Google Scholar 

  • Perales-Puchalt A, Legro RS (2013): Ovulation induction in women with polycystic ovary syndrome. Steroids 78: 767–772

    Article  PubMed  Google Scholar 

  • Savage MO, Drake WM, Carroll PV, Monson JP (2004): Transitional care of GH deficiency: when to stop GH therapy. Eur J Endocrinol 151 Suppl 1: S61–65

    Google Scholar 

  • Striegel H, Simon P (2007): Doping: High-Tech-Betrug im Sport. Internist: 48: 737–742

    Article  PubMed  Google Scholar 

  • van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2013): Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589–1597

    Google Scholar 

  • van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2011): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011 Feb 16; 2: CD00535–4

    Google Scholar 

  • van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2012): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update 18: 11–1

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2014). Hypophysen- und Hypothalamushormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43487-1_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43486-4

  • Online ISBN: 978-3-662-43487-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation